The primary objectives of this phase I clinical trial were to evaluate the safety and tolerability of escalating doses of RO4929097 in combination with cediranib, to characterise dose-limiting toxicities (DLTs) and to determine the recommended dose for phase 2 trials (RP2D).
This study found dose-response evidence for risk of heart disease and stroke among atomic bomb survivors over the radiation dose range 0-4 Gy (mostly 0-2 Gy) based on well characterised individual doses and essentially complete ascertainment of mortality over the period of five to 58 years after exposure to radiation.
Such higher doses represented the third type of consumption identified in this study and was characterised by doses much higher than recommended, with those describing codeine and ibuprofen (12.8 mg and 200 mg/tablet, respectively) compound tablet use, for example, reporting daily consumption between 32 and 64 tablets: I would take eight in one day.
Anthracycline-related cardiac toxicity is characterised by dose-related and irreversible loss of cardiac myocytes.
The control SN or SC peptides did not significantly influence NO production and sGAG content in the presence and absence of 1400 W. We next characterised the dose-response effect of NT and CT peptides on the production of IL-1β and TNFα in constructs cultured for 48 hours.
The primary objectives were: (i) to determine the maximum-tolerated (MTD) dose, (ii) to characterise the dose-limiting toxicities (DLTs) and (iii) to investigate the pharmacokinetics of each agent, in particular a possible influence of tipifarnib on the pharmacokinetics of gemcitabine and cisplatin.
These data show a hormetic response to simvastatin on RMEC migration, characterised as low-dose stimulation and high-dose inhibition.
Once the challenge infection of IFNAR −/− mice with AHSV-4 had been characterised and that doses in the order of 106 pfu/mouse induced clinical signs, viraemia and significant levels of lethality, we evaluated the protective efficacy of a recombinant MVA expressing VP2 of AHSV-4 (MVA-VP2).
As the safety and tolerability profile of DHA and PQP has been well characterised at the doses proposed for the present study, it was considered acceptable to adopt this approach in the present study that would result in more patients receiving DHA/PQP.
Our results are particularly relevant in the face of growing use of diagnostic radiation characterised by higher doses (such as computed tomography scans) in children.
More work is needed to characterise the dose-response relationships.
